{
    "clinical_study": {
        "@rank": "35161", 
        "arm_group": [
            {
                "arm_group_label": "Group 1 (FK949E lower dose)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Group 2 (FK949E middle dose)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Group 3 (FK949E higher dose)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "A study was to evaluate the safety and plasma concentration changes of quetiapine after\n      repeated administration of FK949E (extended-release formulation of quetiapine) in patients\n      with major depressive disorder (MDD)."
        }, 
        "brief_title": "Oral Multiple-dose Study in Patients With Major Depressive Disorder", 
        "completion_date": {
            "#text": "May 2011", 
            "@type": "Actual"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "The objective of the study was to evaluate the safety and pharmacokinetics of multiple oral\n      doses of FK949E (extended-release formulation of quetiapine) of three doses in patients with\n      major depressive disorder (MDD)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of major depressive disorder by the M.I.N.I. according to the DSM-IV-TR\n\n          -  Female patients of childbearing potential with a negative serum pregnancy test result\n             and who were willing and able to use a reliable method of birth control during the\n             study.\n\n          -  Patients who could understand and comply with the requirements of the study, as\n             judged by the investigator/sub-investigator.\n\n        Exclusion Criteria:\n\n          -  A current or past history of a DSM-IV-TR Axis I disorder other than major depressive\n             disorder within 6 months prior to provision of written informed consent.\n\n          -  Diagnosis of a DSM-IV-TR Axis II disorder that was considered to have a major impact\n             on the patient's current psychiatric status.\n\n          -  A history of substance or alcohol abuse or dependence excluding caffeine and\n             nicotine.\n\n          -  Patients who were unable to abstain from drugs that induce or inhibit the\n             drug-metabolizing enzyme CYP3A4 from 14 days prior to screening assessment and\n             throughout the study period.\n\n          -  Patients showing evidence or signs of renal or hepatic failure, serious heart\n             disease, cerebrovascular disease, viral hepatitis B or C, or acquired\n             immunodeficiency syndrome (AIDS) (carrier).\n\n          -  Patients being treated for hypertension or patients with clinical finding that in the\n             opinion of the investigator/sub-investigator could be negatively affected by the\n             study or that would affect the study results (e.g., hypertension, unstable angina).\n\n          -  Patients with concomitant hypotension or orthostatic hypotension (hypotension is\n             defined as systolic blood pressure of less than 100 mmHg)\n\n          -  Conditions that could affect absorption and metabolism of the study medication (e.g.,\n             malabsorption syndrome, liver disease)\n\n          -  A current diagnosis of malignant tumor unless in remission for at least 5 years\n             (except basal or squamous cell skin carcinoma).\n\n          -  A history of transient ischemic attack (TIA).\n\n          -  A history of seizure disorder, except for febrile convulsions\n\n          -  Application of electroconvulsive therapy within 90 days prior to the start of study\n             drug administration\n\n          -  Use of a depot antipsychotic injection and inability to be off the drug for a period\n             of twice the dosing interval prior to screening assessment and throughout the study\n             period\n\n          -  A score of \u2265 3 on the HAM-D17 Item (suicide) or a suicide attempt within the past 6\n             months. Patients judged to be at serious suicidal or homicidal risk in the opinion of\n             the investigator/sub-investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924520", 
            "org_study_id": "6949-CL-0009"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group 1 (FK949E lower dose)", 
                "Group 2 (FK949E middle dose)", 
                "Group 3 (FK949E higher dose)"
            ], 
            "description": "Oral", 
            "intervention_name": "FK949E", 
            "intervention_type": "Drug", 
            "other_name": "extended-release formulation of quetiapine"
        }, 
        "intervention_browse": {
            "mesh_term": "Quetiapine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Antipsychotic", 
            "FK949E", 
            "Quetiapine"
        ], 
        "lastchanged_date": "August 14, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase I Study of FK949E - Phase I Oral Multiple-dose Study in Patients With Major Depressive Disorder", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum plasma concentration (Cmax) of unchanged quetiapine", 
                "safety_issue": "No", 
                "time_frame": "for 24 hours after dosing"
            }, 
            {
                "measure": "AUC24h (area under the curve for 24hr) of unchanged quetiapine", 
                "safety_issue": "No", 
                "time_frame": "for 24 hours after dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924520"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "trough value of plasma concentration of unchanged quetiapine", 
                "safety_issue": "No", 
                "time_frame": "for 24 hours after dosing"
            }, 
            {
                "measure": "t1/2 of plasma concentration of unchanged quetiapine", 
                "safety_issue": "No", 
                "time_frame": "for 24 hours after dosing"
            }, 
            {
                "measure": "Maximum plasma concentration (Cmax) of quetiapine metabolites", 
                "safety_issue": "No", 
                "time_frame": "for 24 hours after dosing"
            }, 
            {
                "measure": "AUC (area under the curve) of quetiapine metabolites", 
                "safety_issue": "No", 
                "time_frame": "for 24 hours after dosing"
            }, 
            {
                "measure": "trough value of plasma concentration of quetiapine metabolites", 
                "safety_issue": "No", 
                "time_frame": "for 24 hours after dosing"
            }, 
            {
                "measure": "tmax of plasma concentration of quetiapine metabolites", 
                "safety_issue": "No", 
                "time_frame": "for 24 hours after dosing"
            }, 
            {
                "measure": "t1/2 of plasma concentration of quetiapine metabolites", 
                "safety_issue": "No", 
                "time_frame": "for 24 hours after dosing"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, clinical tab tests, vital signs, 12-lead ECGs and physical exam", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 14"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}